NCT06615752RecruitingPhase 1
A Phase I/II Study to Determine the Safety and Efficacy of a Combination of Green Tea and Quercetin With Docetaxel in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science1 site in 1 country99 target enrollmentStarted: October 1, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 99
- Locations
- 1
- Primary Endpoint
- Efficacy evaluated with blood prostate specific antigen (PSA) level
Study Overview
Brief Summary
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination.
Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Male patients 18 years or older
- •Diagnosed with metastatic prostate cancer
- •History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
- •Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
- •Clinical decision to start doc infusion with prednisone treatment
- •Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
- •Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
- •Adequate renal function (serum creatinine level within normal limits)
- •At least a 6-month or greater life expectancy
- •Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention
Exclusion Criteria
- •Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
- •Any comorbid condition that would preclude the administration of docetaxel/prednisone
- •Ongoing alcohol abuse
- •Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
- •Prior allergic reaction to tea, tea products or quercetin supplements
- •Allergies to multiple food items or nutritional supplements
Arms & Interventions
green tea and quercetin
Experimental
Green tea and quercetin capsules will be administered in combination with docetaxel treatment.
Intervention: green tea and quercetin + docetaxel (Drug)
placebo
Placebo Comparator
Placebo capsules will be administered in combination with docetaxel treatment as comparison.
Intervention: Placebo + docetaxel (Drug)
Outcomes
Primary Outcomes
Efficacy evaluated with blood prostate specific antigen (PSA) level
Time Frame: From enrollment to the end of treatment at 11 weeks
Blood PSA will be measured at baseline, 1st day of each cycle of docetaxel treatment (21 days per cycle, for 3 cycles), and at the end of the intervention.
Secondary Outcomes
- circulating tumor DNA level (ctDNA) analyzed by next generation sequencing(From the start of intervention at 3 weeks to the end of treatment at 11 weeks.)
- tumor burden by CT detection(From the start of intervention at 3 weeks to the end of treatment at 11 weeks.)
- Adverse events graded by using NCI CTCAE criteria(From the start of intervention at 3 weeks to the end of treatment at 11 weeks.)
- Area under curve (AUC) of blood green tea, quercetin, and docetaxel(On the 1st day of cycle 1 (each cycle is 21 days, 3 cycles total) of the dose escalation study.)
- Maximum concentrations (Cmax) of blood green tea, quercetin, and docetaxel(On the 1st day of cycle 1 (each cycle is 21 days, 3 cycles total) of the dose escalation study.)
- Time taken to reach the maximum concentration (Tmax)(On the 1st day of cycle 1 (each cycle is 21 days, 3 cycles total) of the dose escalation study.)
Investigators
Piwen Wang
Associate Professor
Charles Drew University of Medicine and Science
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing SurgeryAdenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate CancerNCT01912820Jonsson Comprehensive Cancer Center32
Terminated
Not Applicable
A Pilot Trial to Assess the Effects of Green Tea in the Prevention of Therapy-Induced MucositisMucositisNCT00176514University of Medicine and Dentistry of New Jersey37
Completed
Phase 1
Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's EsophagusBarrett EsophagusNCT00233935National Cancer Institute (NCI)55
Active, not recruiting
Phase 2
Clinical Trial of Green Tea Catechins in Men on Active SurveillanceProstate AdenocarcinomaProstate CancerNCT04300855H. Lee Moffitt Cancer Center and Research Institute115
Completed
Not Applicable
Effects of Green Tea Extracts on Gastric Mucosal ProtectionFunctional DyspepsiaNCT04742985Pusan National University Yangsan Hospital24